GSK

Plymouth, United States Founded: 2022 • Age: 4 yrs Acquired By GSK
Precision combination therapies for cancer drivers are developed by IDRx.

About GSK

GSK is a Healthcare company based in Plymouth (United States) founded in 2022 by Nicholas Lydon, George Demetri, and Alexis Borisy, and was acquired by GSK in January 2025. Precision combination therapies for cancer drivers are developed by IDRx. It operates on a Direct-to-Consumer (D2C) and Professional Services model. GSK has raised $242 million across 2 funding rounds from investors including Blackstone, Merck and RA Capital. GSK offers products and services including Respiratory Treatments, Oncology Therapies, HIV Medications, and Infectious Disease Solutions. Its focus areas include Pharmaceuticals and Biopharmaceuticals. Its legal entity is GSK plc. Its competitors include Intima Bioscience, Ilico Genetics and Kupffer Biotherapeutics; 1 of its 3 listed competitors has raised funding.

Company details

GSK, a leading biopharmaceutical company, is focused on uniting science, technology, and talent to address diseases. Operations are centered in therapeutic areas such as respiratory, immunology, oncology, HIV, and infectious diseases. Solutions are developed to improve global health access, particularly in lower-income regions. Commitment is shown towards environmental sustainability and ethical standards. Research and development efforts are prioritized to innovate treatments and positively impact 2.5 billion people by the decades end.

  • Headquarters Plymouth, United States
  • Founders Nicholas Lydon, George Demetri, Alexis Borisy
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Phone
    β€’β€’β€’β€’ β€’β€’β€’β€’
  • Website idrx.com
  • Social LinkedIn X Facebook Instagram YouTube
  • Acquired by GSK (Jan 2025)
  • Legal Name Gsk Plc
Operational Areas
Key Metrics
  • Total Equity Funding
    $242M (USD)

    in 2 rounds

  • Latest Funding Round
    $120M (USD), Series B

    Aug 2024

  • Investors
    Blackstone

    & 10 more

  • Acquired by
    GSK

    (Jan 2025)

Products & Services of GSK

GSK offers a comprehensive portfolio of products and services, including Respiratory Treatments, Oncology Therapies, HIV Medications, and Infectious Disease Solutions.

Respiratory Treatments
Pharmaceuticals

Solutions for respiratory conditions are developed and provided.

Oncology Therapies
Pharmaceuticals

Cancer treatments are researched and offered for patients.

HIV Medications
Pharmaceuticals

HIV therapies are created to manage the condition.

Infectious Disease Solutions
Pharmaceuticals

Treatments for infectious diseases are developed and distributed.

Apps and channels of GSK

its YouTube channel ViiV Healthcare has 133 subscribers and 30 videos.

ViiV Healthcare
YouTube 133 subscribers 30 videos Autos & Vehicles
Open channel

Videos from GSK

The most watched videos on GSK's YouTube channel, ViiV Healthcare (133 subscribers). Click a video to play it here.

Bridging the gap between clinical trials and real life in HIV care
532.5K views
The potential of bNAbs
11.4K views
Take My Hand
2.2K views
We can end the HIV epidemic, FULL STOP.
1.9K views

More on ViiV Healthcare.

Funding Insights of GSK

GSK has successfully raised a total of $242M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $120 million completed in August 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $242M
  • Total Rounds 2
  • Last Round Series B β€” $120M
  • First Round $122M

    (Aug 2022)

  • Investors Count 10

All 2 funding rounds of GSK with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Aug 2024$120MSeries B–RA Capital Management
Aug 2022$122MSeries A–a16z, Casdin Capital
–
Valuation history

11 investors in total: 11 institutional.

Investors in GSK

GSK has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Blackstone, Merck and RA Capital.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Venture capital is provided to healthcare startups by Commodore Capital.
commodorecapital.comNew York, United States
Diversified investment management is provided across multiple asset classes.
1985blackstone.comNew York, United States
Early-stage and late-stage biotech and finance companies are funded.
rockspringscapital.comBaltimore, United States
Venture capital investments in technology sectors are handled by Andreessen Horowitz.
a16z.com
Investing in Life Sciences sectors like Healthcare and Biotechnology.
casdincapital.com
PE firm investing in the US
nextechinvest.comZurich, Switzerland
Limited information is provided about Forge Life Science Partners.
forgelsp.com
RA Capital is engaged in evidence-based investing in healthcare and life sciences.
2004racap.comBoston, United States
Merck is engaged in science and technology solutions globally.
1668merckgroup.comDarmstadt, Germany
Evrys Bio is focused on developing broad-spectrum antiviral therapies.
forgelifescience.comDoylestown, United States
Premium access

Investor details for GSK

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of GSK

5 people are tracked at GSK (3 in leadership, 2 in team).

NameRoleGroup
Nicholas Lydon
Co-FounderLeadership
George Demetri
Co-FounderLeadership
Alexis Borisy
Co-FounderLeadership
Jorge Conde
Board MemberTeam
Vivek Kadambi
Senior AdvisorTeam
Premium access

Complete people profiles for GSK

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of GSK

4 dated milestones of GSK across 3 years, from founding to its latest funding, stage changes and deals.

  1. Founded GSK is founded.
  2. Funding First funding round of $122.0M.
  3. Funding Latest funding round, Series B, of $120.0M.
  4. Exit Acquired by GSK.

Competitors of GSK

GSK has 3 listed competitors in our database, 1 of them funded. They include Intima Bioscience, Ilico Genetics and Kupffer Biotherapeutics.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
intimabioscience.com2014New York, United States
Therapeutics for gastrointestinal cancer are developed using CRISPR gene-editing.
ilicogenetics.com2020Bethlehem, United States$457,735
Developer of diagostic test for detection of gastric cancer
kupfferbio.com2019Burlingame, United States
Develops innovative technologies for anticancer therapies targeting gastrointestinal cancers.
Premium access

Detailed competitors of GSK

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Top companies in Oncology

3 companies that operate in the same segment as GSK (Oncology) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
mRNA-based therapeutics for diseases including cancer and infections are developed.
2010Cambridge, Massachusetts, United StatesUSD 2.78 BUSD 1.94 B5,800
Digital sequencing technology for cancer detection is developed.
2012Redwood City, California, United StatesUSD 557.5 MUSD 982.02 M4,867
Circulating tumor DNA is screened for early cancer detection.
2016Menlo Park, California, United StatesUSD 2 BUSD 147.17 M1,141
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Gsk

Premium access

Complete news archive for GSK

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about GSK

GSK was founded in 2022.

GSK is headquartered in Plymouth, United States. It is registered at Plymouth, Massachusetts, United States.

GSK is a funded company, having raised a total of $242M across 2 funding rounds to date. The company's 1st funding round was a Series A of $122M, raised on Aug 2022.

GSK, a leading biopharmaceutical company, is focused on uniting science, technology, and talent to address diseases. Operations are centered in therapeutic areas such as respiratory, immunology, oncology, HIV, and infectious diseases. Solutions are developed to improve global health access, particularly in lower-income regions. Commitment is shown towards environmental sustainability and ethical standards. Research and development efforts are prioritized to innovate treatments and positively impact 2.5 billion people by the decades end.

GSK's top competitors include Ilico Genetics, Intima Bioscience and Kupffer Biotherapeutics.

GSK offers Respiratory Treatments, Oncology Therapies, HIV Medications, and Infectious Disease Solutions.

GSK has 11 investors. Key investors include Blackstone, Merck, RA Capital, GSK, and Commodore Capital.

GSK operates through Gsk Plc.

Yes. GSK was acquired by GSK in January 2025.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available